Using Whole-Exome Sequencing to Identify Inherited Causes of Autism

Timothy W. Yu,1,2,3,4,5,6,7,32,* Maria H. Chahrour,1,2,3,4,5,7,32 Michael E. Coulter,1,2,3,5 Sam Jiralerspong,8 Kazuko Okamura-Ikeda,9 Bulent Ataman,10 Klaus Schmitz-Abe,1,2,5 David A. Harmin,10 Mazhar Adli,11 Athar N. Malik,10 Alissa M. D’Gama,3 Elaine T. Lim,12 Stephan J. Sanders,13 Ganesh H. Mochida,1,2,3,5,6 Jennifer N. Partlow,1,2,3 Christine M. Sunu,1,2,3 Jillian M. Felie,1,2,3 Jacqueline Rodriguez,1,2,3 Ramzi H. Nasir,5,14 Janice Ware,5,14 Robert M. Joseph,4,18 R. Sean Hill,1,2,3,5 Benjamin Y. Kwan,16 Muna Al-Saffar,1,2,17 Nahit M. Mukaddes,18 Asif Hashmi,19 Soher Balkhy,20 Generoso G. Gascon,6,18,21 Fuki M. Hisama,22 Elaine LeClair,5,14 Annapurna Poduri,5,23 Ozgur Oner,24 Samira Al-Saad,25 Sadika A. Al-Awadi,26 Laila Bastaki,26 Tawfeg Ben-Omran,27,28 Ahmad S. Teebi,27,28 Lihadh Al-Gazali,17 Valsamma Eapen,29 Christine R. Stevens,7 Leonard Rappaport,4,5,14 Stacey B. Gabriel,7 Kyriacos Markianos,1,2,5 Matthew W. State,13 Michael E. Greenberg,10 Hisaaki Taniguchi,9 Nancy E. Braverman,8 Eric M. Morrow,4,30,31 and Christopher A. Walsh1,2,3,4,5,7,*

1Division of Genetics, Department of Medicine
2Manton Center for Orphan Disease Research
3Howard Hughes Medical Institute
Boston Children’s Hospital, Boston, MA 02115, USA
4The Autism Consortium, Boston, MA 02115, USA
5Harvard Medical School, Boston, MA 02114, USA
6Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA
7Program in Medical and Population Genetics, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
8Department of Human Genetics and Pediatrics, McGill University, Montreal Children’s Hospital Research Institute, Montreal, QC H3H 1P3, Canada
9Institute for Enzyme Research, The University of Tokushima, Tokushima 770-8501, Japan
10Department of Neurobiology, Harvard Medical School, Boston, MA 02115, USA
11Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA
12Analytic and Translational Genetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA
13Department of Genetics, Center for Human Genetics and Genomics and Program on Neurogenetics, Yale University School of Medicine, New Haven, CT 06510, USA
14Division of Developmental Medicine, Boston Children’s Hospital, Boston, MA 02115, USA
15Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA 02118, USA
16Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada
17Department of Paediatrics, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates
18Istanbul Faculty of Medicine, Department of Child Psychiatry, Istanbul University, Istanbul 34452, Turkey
19Armed Forces Hospital, King Abdulaziz Naval Base, Jubail 31951, Kingdom of Saudi Arabia
20Department of Neurosciences and Pediatrics, King Faisal Specialist Hospital and Research Center, Jeddah 21499, Kingdom of Saudi Arabia
21Clinical Neurosciences and Pediatrics, Brown University School of Medicine, Providence, RI 02912, USA
22Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA 98195, USA
23Department of Neurology, Boston Children’s Hospital, Boston, MA 02115, USA
24Department of Child and Adolescent Psychiatry, Dr Sami Ulus Children’s Hospital, Telsizler, Ankara 06090, Turkey
25Kuwait Center for Autism, Kuwait City 73455, Kuwait
26Kuwait Medical Genetics Center, Kuwait City 72458, Kuwait
27Section of Clinical and Metabolic Genetics, Department of Pediatrics, Hamad Medical Corporation, Doha, Qatar
28Departments of Pediatrics and Genetic Medicine, Weill Cornell Medical College, New York, NY 10065, USA, and Doha, Qatar
29Academic Unit of Child Psychiatry South West Sydney (AUCS), University of New South Wales, Sydney, New South Wales 2170, Australia
30Department of Molecular Biology, Cell Biology and Biochemistry
31Department of Psychiatry and Human Behavior
Brown University, Providence, RI 02912, USA
32These authors contributed equally to this work
*Correspondence: timothy.yu@childrens.harvard.edu (T.W.Y.), christopher.walsh@childrens.harvard.edu (C.A.W.)
http://dx.doi.org/10.1016/j.neuron.2012.11.002

SUMMARY

Despite significant heritability of autism spectrum disorders (ASDs), their extreme genetic heterogeneity has proven challenging for gene discovery. Studies of primarily simplex families have implicated de novo copy number changes and point mutations, but are not optimally designed to identify inherited risk alleles. We apply whole-exome sequencing (WES) to ASD families enriched for inherited causes due to consanguinity and find familial ASD associated...
with biallelic mutations in disease genes (AMT, PEX7, SYNE1, VPS13B, PAH, and POMGNT1). At least some of these genes show biallelic mutations in nonconsanguineous families as well. These mutations are often only partially disabling or present atypically, with patients lacking diagnostic features of the Mendelian disorders with which these genes are classically associated. Our study shows the utility of WES for identifying specific genetic conditions not clinically suspected and the importance of partial loss of gene function in ASDs.

INTRODUCTION

Despite studies suggesting that autism spectrum disorders (ASDs) are significantly heritable, the basis of this heritability remains largely unexplained (Devlin and Scherer, 2012). Autism is characterized by the triad of communication deficits, abnormal social interests, and restricted and repetitive behaviors. Genome-wide association studies (GWAS) have so far detected no strong contribution of common alleles (State, 2010), motivating renewed interest in rare variants (Malhotra and Sebat, 2012). Transmitted, rare copy number variants (CNVs), such as 16p11.2 microdeletion/duplication and 15q11.2-q13 duplication have been found to contribute, although the total number of cases accounted for by these conditions is small (Levy et al., 2011; Pinto et al., 2010; Weiss et al., 2008). Significant roles have also been demonstrated for diverse, de novo CNVs (Levy et al., 2011; Sanders et al., 2011; Sebat et al., 2007) and more recently, de novo, protein-altering point mutations (LOSSIFOV et al., 2012; NEALE et al., 2012; O’ROAK et al., 2011; O’ROAK et al., 2012). In the cohorts examined, de novo events may be projected to account for up to 15%-20% of ASD cases. Despite the high total rate of de novo point mutations, estimates of the number of contributing loci to autism susceptibility are in the several hundreds, so that validating specific causative genes is a significant challenge, since recurrent mutation in any given gene is so uncommon. Nonetheless, these studies have been successful at elucidating gene dosage-sensitive ASD molecular pathways, since the typical mutations observed are loss/disruption, or sometimes gain, of one functional copy of a gene or contiguous genes, rather than biallelic mutations of both copies of a gene. However, despite the importance of de novo mutations, much of the heritability of ASDs remains unaccounted for (Devlin and Scherer, 2012).

We hypothesized that at least some cases of autism reflect rare, inherited point mutations that existing study designs, often involving families with one or two affected individuals, are not designed to capture. Consanguineous and multiplex pedigrees have been extremely useful for identifying inherited mutations responsible for rare heritable conditions in the setting of extreme genetic heterogeneity, because single families can provide substantial genetic linkage evidence (LANDER and BOTSTEIN, 1987; WOODS et al., 2006). Applying high-throughput sequencing to such families has been extremely useful in identifying recessive causes of intellectual disability (NAJMABADI et al., 2011). The potential role of biallelic mutations in ASDs is strongly supported by a number of syndromic recessive conditions that have already been associated with autistic symptoms (Betancur, 2011). Additional evidence supporting a role of biallelic mutations comes from studies that have implicated homozygous CNVs (Levy et al., 2011; Morrow et al., 2008) and long homozygous intervals as significantly associated with ASDs (CASEY et al., 2012). Finally, a recent whole-exome sequencing (WES) study has suggested a role for biallelic point mutations in a subset of patients with ASDs that show long runs of homozygosity (CHahrour et al., 2012).

In this study, we apply WES to a cohort of consanguineous and/or multiplex families with ASD that also show shared ancestry between the parents, typically as cousins. We find several families where mapping and sequence analysis allow the identification of specific causative mutations and show that many of these mutations represent partial loss of function in genes where null mutations cause distinctive Mendelian disorders. These hypomorphic mutations confirm the complex and heterogeneous nature of ASDs, but also highlight the importance of WES in identifying specific genetic causes underlying this heterogeneity.

RESULTS

Identifying Inherited Mutations in Three ASD Families

We studied an ASD cohort recruited by the Homozygosity Mapping Collaborative for Autism (HMCA), an international, multicenter effort to identify genetically informative ASD families with consanguinity and/or multiple affected individuals (MORROW et al., 2008). We first performed genome-wide linkage analysis on the most informative families, using high-resolution single nucleotide polymorphism (SNP) arrays, reasoning that some families would show homozygous, biallelic mutations embedded within larger blocks of homozygosity inherited from the ancestor common to both parents. Families were prescreened to exclude those harboring autism-associated CNVs or other known diagnoses (Supplemental Experimental Procedures). Three families provided particularly strong genetic power to localize potential disease loci.

The first family had three children affected with ASD and two unaffected children, born to parents who were first cousins (Figure 1A; Table 1B; see Supplemental Text available online). Mapping under a single locus, biallelic model (i.e., allowing for both homozygous and compound heterozygous mutations) excluded 99.3% of the genome and revealed a single linkage peak centered at 3p21.31, in a large homozygous interval, reaching the maximum LOD score obtainable in the pedigree, 2.96 (Figure 1B), suggesting a >900:1 likelihood that the responsible mutation was contained within this homozygous interval. WES of a single affected child was performed. The linked interval contained only a single rare, nonsynonymous change that was absent from known databases and population-matched controls: a homozygous single base substitution in the aminomethyltransferase (AMT) gene, encoding an enzyme essential for the degradation of glycine. The mutation resulted in p.I308F, altering an Ile residue that is highly conserved in all AMT orthologs (Figure 1C) and is packed tightly into a hydrophobic pocket...
(Figure 1D; Okamura-Ikeda et al., 2005). Sanger validation confirmed that the mutation was heterozygous in both parents, homozygous in all affected children, and absent or heterozygous in the two unaffected children.

Mutations in AMT classically cause nonketotic hyperglycinemia (NKH) (Applegarth and Toone, 2004), a neonatal syndrome leading to progressive lethargy, hypotonia, severe seizures, and death within the first year of life (Hamosh and Johnston, 2001). Patients with neonatal NKH have impaired activity of the glycine cleavage system, leading to abnormal elevation of glycine levels in serum or cerebrospinal fluid (CSF). Rarer, atypical forms of NKH have been described in association with hypomorphic, missense AMT mutations (Applegarth and Toone, 2001; Dinopoulos et al., 2005), manifesting as later age of clinical onset, delays in expressive language, behavioral problems, and variable or absent seizures. Clinical and biochemical evidence suggests that the p.I308F mutation is hypomorphic. While individually nondiagnostic, the three affected children in this family exhibited a range of neurologic symptoms that in aggregate were strongly suggestive of NKH (Supplemental Text). The eldest child was twelve years old and had, in addition to a diagnosis of ASD, a history of severe epilepsy, with first seizures presenting by age 10 months, very consistent with NKH. The second child was nine years old and also suffered from a combination of autism and epilepsy, though her seizures were milder. The third child was two years old, suffered from language and motor delays, and carried a presumptive PDD diagnosis. He had had only a single febrile seizure. Though the two older children had had plasma amino acid screening that disclosed no abnormalities, milder forms of NKH typically have no abnormalities on serum biochemical analyses (Applegarth and Toone, 2001; Dinopoulos et al., 2005).

Direct biochemical analysis of the p.I308F mutation confirms that it has reduced activity. While wild-type AMT is fully soluble at 30°C when expressed in bacteria, mutant AMT p.I308F was very poorly soluble (Figure 1E), indicating a protein folding defect, similar to that observed with NKH-associated AMT mutations (Figure S1; Table S1). This defect could be rescued by co-expressing GroES and GroEL heat-shock proteins at 22°C (Figure 1E). AMT p.I308F, even after solubilization, retained only 45% (SD 4.1%) and 1.8% (SD 0.5%) of wild-type glycine cleavage and glycine synthesis specific activity, respectively, when assayed enzymatically (Figures 1F and S2). When compared to classical NKH-associated alleles, glycine cleavage activity of AMT p.I308F is at the mild end of the range of previously reported values (Figures 1F and S2), further suggesting that the affected autistic children in this family suffer from undiagnosed, atypical NKH presenting as ASD and seizures.

A second consanguineous family had three children diagnosed with ASD and three unaffected children, born to unaffected parents who were first cousins (Figure 2A; Table 1B; Supplemental Text). Parametric mapping excluded 97.2% of the genome and established linkage to a homozygous interval on 6p23 (Figure 2B) (LOD 2.78, the maximum obtainable in the pedigree, under a recessive model, indicating a 600:1 likelihood that this interval contained the disease-causing mutation). WES identified only one variant, absent from known databases and population-matched controls, in this region that was predicted to be pathogenic: PEX7 p.W75C. This change was homozygous and altered a highly conserved Trp residue within a WD-40 repeat of the predicted protein (Figures 2C and 2D). Sanger validation confirmed that this mutation was heterozygous in both parents, and heterozygous or wild-type in unaffected children. PEX7 encodes a receptor required for import of PTS2 (peroxisome targeting signal 2)-containing proteins into the peroxisome (Braverman et al., 1997). Null mutations in PEX7 cause rhizomelic chondrodysplasia punctata (RCDP), an inborn metabolic syndrome of abnormal facies, cataracts, skeletal dysplasia, epilepsy, and severe psychomotor defects, with most cases not surviving beyond two years of age (Braverman et al., 2002; Braverman et al., 1997; Motley et al., 1997). The affected children in this family, however, ranged in age from 18 to 31 years. They were not dysmorphic and did not exhibit skeletal dysplasia, though two had cataracts and two had epilepsy (Supplemental Text). The cataracts and seizures in particular suggested partial loss of PEX7 function, since rare, atypical RCDP cases associated with hypomorphic compound heterozygous or homozygous mutations have been described that have some but not all of the features of the classical syndrome, lacking dysmorphic features and showing only intellectual disability with variable cataracts (Braverman et al., 2002).

To evaluate whether the p.W75C missense change in this family could be pathogenic, we assayed its ability to rescue peroxisomal import in cultured fibroblasts from a RCDP patient. In RCDP fibroblasts, fluorescent mCherry fused to the PTS2 peroxisomal targeting sequence fails to be imported into peroxisomes and remains cytosolic (Figure 2E). Cotransfection of wild-type PEX7 fully restores peroxisomal import (Figure 2E). In contrast, transfection with PEX7 p.W75C failed to rescue (Figure 2E): the majority of cells showed cytosolic PTS2-mCherry, although a fraction showed partial rescue. To characterize this effect, we utilized a semi-quantitative assay of peroxisomal import. The PTS2 proteins thioleste, phytanoyl-CoA hydroxylase (PhyH), and alkylglycerone phosphate synthase (AGPS) are imported into the peroxisome and proteolytically processed into smaller, mature forms (Figure 2F). Peroxisomal uptake is thus reflected in the ratio of the mature protein to the preprotein. In RCDP cells, these three proteins all remain in the preprotein state, reflecting failure of peroxisomal import. Transfection of wild-type PEX7 fully restores processing, whereas transfection of PEX7 p.W75C produced only partial processing (Figure 2F). These results demonstrate that this allele is pathogenic, but partial loss of function, consistent with these individuals not exhibiting full features of the RCDP syndrome.

To our knowledge, a link between mild RCDP and ASDs has not been described previously. However, two previously reported patients with biochemical evidence of RCDP and cataracts, but lacking the dysmorphic features of RCDP, were found to be compound heterozygous for partial loss-of-function PEX7 mutations (Braverman et al., 2002): one was originally described as intellectually disabled and the second as neurotypical. We recontacted these patients. A review of clinical records and reexamination of the first child revealed that she had subsequently been diagnosed with ASD, and the second child was diagnosed with severe ADHD, providing additional examples of the range of clinical expressivity of mild mutations in PEX7. Partial loss of
Figure 1. Identification of Mutations in AMT in a Family with ASD

(A) AU-1700, a Saudi family with three children affected by autism. Shaded symbols indicate affected individuals. The triangle represents a miscarriage. WES was performed on samples from individuals indicated with a star. Genotyping by Sanger sequencing in additional family members was performed where indicated (+, reference allele; −, alternate allele).

(B) Mapping to a locus on chromosome 3. Genome-wide linkage plot (top) and maximum obtainable LOD score in the family across the interval (bottom).

(C) Expression of huTs at 30 °C for 22 hours

(D) Expression of huTs at 22 °C for 44 hours

(E) Co-expression of huTs with GroEL at 22 °C for 44 hours

Figure 1 legend continued on next page.
function for one of the alleles in these patients, S25F, was verified in fibroblast assays (Figures 2E and 2F).

Analysis of a third large family pointed to a candidate autism gene potentially implicated in synaptic plasticity, SYNE1. In this family, five children were born to parents who were double first cousins. Four were affected with autism and the fifth child was unaffected (Figure 3A; Supplemental Text). The family showed linkage to two loci on chromosome 6q25 and 7q33 (LOD 2.83, maximal obtainable in the pedigree, indicating a >670:1 chance that the disease-causing gene lies in one of these intervals) (Figure 3B). WES was performed for the entire nuclear family. No rare, protein-altering variants were found in the 7q33 linkage interval, whereas 6q25 harbored only one protein-altering variant, absent from known databases and population-matched controls, that segregated with disease: a homozygous missense change in SYNE1 (p.L3206M) (Table 1). SYNE1 has previously been implicated as an ASD gene candidate by the presence of a de novo single nucleotide variant in a patient with ASD (O’Roak et al., 2011) and has been implicated in bipolar disorder in a GWAS study (Sklar et al., 2011; Figure 3C). Truncating, presumably null, mutations in SYNE1 cause cerebellar ataxia (Gros-Louis et al., 2007), and a recessive form of arthrogryposis multiplex congenita (Attali et al., 2009; Figure 3C), again suggesting that the ASD-associated allele may be homomorphic, since the phenotype is milder. SYNE1 p.L3206M alters a highly conserved residue that lies within a spectrin repeat (Figure 3D; SIFT score 0.01).

Full-length SYNE1 encodes a large 8,797 amino acid protein with two N-terminal actin-binding domains, multiple spectrin repeats, a transmembrane domain, and a C-terminal KASH domain. The SYNE1 mutation identified here is predicted to map to exon 61 of the full-length transcript (RefSeq NM_182961), although the SYNE1 locus is complex, with many predicted alternative splice forms (Simpson and Roberts, 2008).

To identify what human transcript(s) might be affected by the p.L3206M mutation, we mapped truncation and splice site mutations in human neurons using ChIPseq (Figure 3E). ChIPseq using antibodies to H3K4Me3, a mark associated with active promoters (Ernst et al., 2011), and to H3K27Ac, a mark associated with enhancer elements (Heintzman et al., 2009), demonstrated mapped read peaks corresponding to at least four major truncation and splice site mutations within the SYNE1 locus (P1–P4), one of which (P3) lies immediately upstream of the p.L3206M mutation (Figure 3E). 5′ and 3′ RACE (data not shown) confirmed the existence of at least one polyadenylated transcript emanating from this promoter, corresponding to GenBank mRNA clone BC039121, encompassing exons 57–63 of the predicted full-length SYNE1 mRNA. This is the minimal confirmed transcript that overlaps the p.L3206M mutation, although contributions of additional or even full-length transcripts cannot be excluded.

SYNE1 has been shown to have roles in cellular nuclear migration in C. elegans and Drosophila (Starr and Han, 2002; Zhang et al., 2002), anchoring of synaptic nuclei with postsynaptic membranes at the vertebrate neuromuscular junction (Grady et al., 2005), although based upon patients with SYNE1-associated cerebellar ataxia, it has been suggested that vertebrates may have compensatory mechanisms for these two processes and that SYNE1 may have adapted to perform a specialized function in the brain (Gros-Louis et al., 2007). In rodents, a spectrin-rich splice form of SYNE1 called CGP2 has been shown to control dendritic spine shape and glutamate receptor turnover in response to neuronal activity (Cottrell et al., 2004). To test whether SYNE1 might be responsive to neuronal activity, we performed RNaseq on cultured human primary neurons, before and after depolarization. Transcription of full-length SYNE1 was induced 1.27-fold (n = 5, SE 0.06, p = 0.0203, t test, one-tailed) by neuronal activity, and transcription of BC039121 was induced by 1.50-fold (n = 5, SE 0.11, p = 0.0225, t test, one-tailed) across five biological replicates (Figures 3E and S2). This suggests that both full-length SYNE1 and the shorter BC039121 isoform may have neuronal activity-dependent roles in regulating synaptic strength, like other synaptic genes implicated in autism.

**WES for Known Disease Genes**

Our findings of inherited, biallelic, homomorphic ASD mutations in larger families prompted us to ask whether additional cases of ASD might be explained by either unsuspected or atypical presentations of known diseases. Over 450 genes have been identified that, when mutated, have neurocognitive impact (van Bokhoven, 2011). To increase the specificity of our analysis, we chose to analyze a limited subset of 70 of these genes, each associated with a monogenic, autosomal recessive or X-linked neurodevelopmental syndrome in which autistic features have been previously described (Table S2; Betancur, 2011). We also screened for additional alleles of AMT, PEX7, and SYNE1. We used WES to screen for mutations in these genes in a total of 163 consanguineous and/or multiplex families using established heuristic filtering for rare, high penetrance disease (Bamshad et al., 2011; Stitzel et al., 2011) to identify homozygous, compound heterozygous, or hemizygous variants.
### Table 1. Inherited Mutations Identified in ASDs

**(A) Severe Mutations**

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Known Disease Association</th>
<th>Family</th>
<th>Structure</th>
<th>Consanguinity</th>
<th># Affected</th>
<th># Unaffected</th>
<th>Linkage</th>
<th>Primary Phenotype</th>
<th>Additional Phenotypes</th>
</tr>
</thead>
<tbody>
<tr>
<td>MECP2 p.E483X</td>
<td>Rett syndrome, ASD</td>
<td>AU-5400</td>
<td>Multiplex</td>
<td>No</td>
<td>2 (2M)</td>
<td>—</td>
<td>Yes</td>
<td>Autism</td>
<td>—</td>
</tr>
<tr>
<td>NLGN4X p.Q329X</td>
<td>Nonsyndromic X-linked ID and/or ASD</td>
<td>AU-5700</td>
<td>Simplex</td>
<td>Yes</td>
<td>1 (M)</td>
<td>1</td>
<td>Yes</td>
<td>Autism</td>
<td>—</td>
</tr>
<tr>
<td>PAH p.198_205 del</td>
<td>Phenylketonuria</td>
<td>AU-13100</td>
<td>Simplex</td>
<td>Yes</td>
<td>1 (M)</td>
<td>2</td>
<td>Yes</td>
<td>Autism</td>
<td>ID</td>
</tr>
<tr>
<td>PAH p.Q235X</td>
<td>Phenylketonuria</td>
<td>AU-4100</td>
<td>Multiplex</td>
<td>Yes</td>
<td>2 (2F)</td>
<td>—</td>
<td>Yes</td>
<td>Autism</td>
<td>—</td>
</tr>
<tr>
<td>VPS13B p.A3943fs</td>
<td>Cohen syndrome</td>
<td>AU-21100</td>
<td>Simplex</td>
<td>Yes</td>
<td>1 (M)</td>
<td>3</td>
<td>Yes</td>
<td>Autism</td>
<td>ID, dysmorphic features, hyperextensible joints</td>
</tr>
</tbody>
</table>

**(B) Hypomorphic Mutations**

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Known Disease Association</th>
<th>Family</th>
<th>Structure</th>
<th>Consanguinity</th>
<th>#Affected</th>
<th># Unaffected</th>
<th>Linkage</th>
<th>Primary Phenotype</th>
<th>Additional Phenotypes</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMT p.I308F</td>
<td>Nonketotic hyperglycinemia</td>
<td>AU-1700</td>
<td>Multiplex</td>
<td>Yes</td>
<td>3 (2M, 1F)</td>
<td>2</td>
<td>Yes</td>
<td>Autism</td>
<td>ID, seizures</td>
</tr>
<tr>
<td>AMT p.D198G</td>
<td>Nonketotic hyperglycinemia</td>
<td>AU-11800</td>
<td>Simplex</td>
<td>Yes</td>
<td>1 (M)</td>
<td>1</td>
<td>Yes</td>
<td>Autism</td>
<td>ID, seizures</td>
</tr>
<tr>
<td>PEX7 p.W75C</td>
<td>Rhizomelic chondrodysplasia punctata</td>
<td>AU-3500</td>
<td>Multiplex</td>
<td>Yes</td>
<td>3 (2M, 1F)</td>
<td>3</td>
<td>Yes</td>
<td>PDD-NOS</td>
<td>ID, seizures, cataracts</td>
</tr>
<tr>
<td>POMGNT1 p.R367H</td>
<td>Muscle–eye–brain disease</td>
<td>AU-13300</td>
<td>Simplex</td>
<td>Yes</td>
<td>1 (M)</td>
<td>1</td>
<td>Yes</td>
<td>Autism</td>
<td>ID</td>
</tr>
<tr>
<td>SYNE1 p.L3206M</td>
<td>Autosomal recessive cerebellar ataxia type 1, arthrogryposis congenita, ASD, bipolar disease</td>
<td>AU-1600</td>
<td>Multiplex</td>
<td>Yes</td>
<td>4 (1M, 3F)</td>
<td>1</td>
<td>Yes</td>
<td>Autism</td>
<td>ID</td>
</tr>
<tr>
<td>VPS13B p.S824A</td>
<td>Cohen syndrome</td>
<td>AU-17800</td>
<td>Simplex</td>
<td>Yes</td>
<td>1 (M)</td>
<td>1</td>
<td>Yes</td>
<td>Autism</td>
<td>ID, dysmorphic features, hyperextensible joints</td>
</tr>
</tbody>
</table>

Severe (nonsense, frameshift) (A) and hypomorphic (missense) (B) mutations in known disease genes were identified in 11 ASD families. M, male; F, female; ID, intellectual disability. See also Tables S3 and S4.
with allele frequencies of less than 1% (dbSNP132, 1000 Genomes Project, NHLBI Exome Sequencing Project, and population-matched controls consisting of 831 exomes from the Middle Eastern population; see Experimental Procedures for details) and which were predicted to be protein altering (missense, nonsense, splice site, or frameshift). Candidate mutations were confirmed by Sanger sequencing in the entire family and were required to segregate with disease status within the family (i.e., homozygous or hemizygous in the affected individuals, inherited in the heterozygous state from parents, and heterozygous or absent from unaffected siblings). An overview of the analytic strategy is shown in Figure 4.

In five families (Tables 1A and S4), our screen revealed molecular genetic diagnoses due to severe loss of function (nonsense or frameshift) hemizygous or homozygous mutations in known genes. One of these was a nonsense mutation in NLGN4X (p.Q329X), found in a single affected male child. NLGN4X is an X-linked gene encoding a neuronal synaptic adhesion molecule, and mutations in NLGN4X have been described in individuals with autism, Asperger syndrome, and intellectual disability (Jamain et al., 2003). This mutation was inherited from an unaffected mother, consistent with prior observations that carrier females may be asymptomatic (Südhof, 2008; Table 1A; Figure S4).

In another family, two male children affected with autism carried a nonsense mutation in the X-linked gene MECP2 (p.E483X), the gene responsible for Rett syndrome (Table 1A). Their mutation was also inherited from the unaffected mother, who was heterozygous (Figure S4). The finding of MECP2 nonsense mutations in this family was unusual since these are typically lethal in males (Chahrour and Zoghbi, 2007), suggesting that this allele is likely hypomorphic. Consistent with this idea, p.E483X is a late truncation predicted to remove only the last four amino acids of the full-length protein.

Two consanguineous families had homozygous nonsense or frameshift mutations in PAH (Table 1A; Figure S4), the cause of phenylketonuria and one of the earliest neurometabolic syndromes described as a cause of ASD (Zecavati and Spence, 2009). These families were confirmed to have phenylketonuria by clinical laboratory testing.

An additional ASD family implicated a syndrome associated with dysmorphic features and microcephaly. We found a homozygous frameshift alteration in VPS13B/COH1 in the proband in a consanguineous family who had ASD and mild dysmorphic features (Figure 5A; Table 1A). The mutation (p.A3943fs) causes truncation of the C-terminal 54 amino acids of VPS13B/COH1. Recessive mutations in VPS13B/COH1 cause Cohen syndrome, characterized by a constellation of intellectual disability, facial dysmorphism, retinal dystrophy, truncal obesity, joint laxity, intermittent neutropenia, and postnatal microcephaly (Hennies et al., 2004) that has previously been associated with autistic symptoms in some cases (Douzou and Petersen, 2011). However, significant variability in the features associated with Cohen syndrome makes clinical diagnosis challenging (Mochida et al., 2004; Seifert et al., 2006). The affected child in our cohort had several features that suggest a diagnosis of Cohen syndrome, including microcephaly (head circumference 49 cm at age 9, <3rd percentile) and the characteristic facial dysmorphisms typically seen in Cohen syndrome (Figures 5B and 5C; Supplemental Text).

In addition to severe loss-of-function mutations, a significant proportion of rare missense variants are also expected to be significantly deleterious (Kryukov et al., 2007), as underscored by our AMT and PEX7 findings. Eleven families were found to have rare, segregating, homozygous or hemizygous missense changes in known genes (Tables 1B, S3, and S4). While some of these may be expected to be functionally silent, we found clinical and/or biochemical evidence supporting their pathogenicity in at least four instances (Table 1B).

In one consanguineous ASD family, we identified a linked homozygous missense change in AMT (p.D198G) in a single affected child with ASD and intellectual disability (Table 1B). This variant was heterozygous in both parents and an unaffected sibling, and disrupts a highly conserved residue of AMT (SIFT score 0.01). Functional assays of AMT p.D198G demonstrated that, like p.I308F and other NKH-associated mutations, p.D198G is poorly soluble (Figure S5). AMT p.D198G also exhibited a temperature-sensitive protein stability defect (Figure S5). Enzyme specific activity was preserved (Figure S5), suggesting that pathogenicity may be due to protein misfolding/stability and not catalytic dysfunction, similar to what is observed for p.G47R, a known NKH-associated AMT mutation (Figure S1; Table S1). These findings suggest that this child may have also suffered from undiagnosed, atypical NKH.

A child affected with ASD and moderate intellectual disability was found to have a homozygous missense change (p.R367H) in POMGNT1 (Table 1B; Figure S4). POMGNT1 is responsible for an inherited dystroglycanopathy characterized by brain malformation, intellectual disability, developmental delay, hypotonia, and myopia; interestingly, rare patients have been reported with severe autistic features (Haliloglu et al., 2004; Hehr et al., 2007). The p.R367H missense variant in this patient disrupts a highly conserved residue, and this exact allele has been reported as causative in a patient with relatively mild clinical disease, as a compound heterozygous mutation in combination with a splice site mutation (Godfrey et al., 2007).

Finally, in another consanguineous family, the single affected child was homozygous for a rare missense variant (p.S824A) in VPS13B (Table 1B; Figure S4). The proband had in retrospect some but not all features of Cohen syndrome (autism with mild facial dysmorphism and joint laxity), consistent with mild versions reported previously (Hennies et al., 2004).

To begin to explore how these results might extend to nonconsanguineous families, we screened for mutations in genes implicated from our cohort (AMT, PEX7, SYNE1, VPS13B, PAH, and POMGNT1) in 612 families from the Simons Simplex Collection (193 trios with parents and affected child, plus 419 quartets with parents, affected child, and unaffected sibling). An analysis of publicly released whole-exome sequence data (Iossifov et al., 2012; O’Roak et al., 2012; Sanders et al., 2012) showed a modest trend toward an excess of biallelic, inherited, rare (MAF < 1%), protein-altering variants in cases (8/612) compared to control siblings (2/419) (p = 0.21, Fisher’s exact test, two-tailed) in at least one of the genes we screened (Table S5). As expected for a nonconsanguineous cohort, all but one were found in the compound heterozygous state. Although functional validation
Figure 2. Identification of Mutations in PEX7 in a Family with ASD

(A) AU-3500, a family with three children affected with ASD. Shaded symbols indicate affected individuals. WES was performed on samples from individuals indicated with a star. Genotyping by Sanger sequencing in additional family members was performed where indicated (+, reference allele; –, alternate allele).

(legend continued on next page)
of all of these mutations is not available, in at least two cases, phenotype data are supportive of the mutations’ pathogenicity. One affected male child was compound heterozygous for two different mutations in VPS13B (p.W963X/p.G2704R). Gly2704 is a highly conserved residue, while p.W963X leads to early truncation of the protein and has been previously reported in Cohen syndrome (Kolehmainen et al., 2004). Review of the clinical phenotype of this individual confirmed that he manifested, in addition to autism, features of Cohen syndrome including prominent microcephaly (<3 SD) and somatic dysmorphisms (Supplemental Text), making the diagnosis of a Cohen syndrome mutation highly likely. A second, unrelated male child affected with autism was compound heterozygous for two rare point mutations in VPS13B, p.S3303R and p.A3691T, both altering highly conserved residues. In addition to being autistic, this child also manifested dysmorphisms of the face and extremities as well as an abnormal hair growth pattern, known to characterize Cohen syndrome. These data confirm that biallelic mutations are also found in nonconsanguineous autism cohorts, but analysis of much larger numbers of genes and patients will be needed to quantify their prevalence.

**DISCUSSION**

Our data combine WES with segregation analysis to demonstrate that biallelic, hypomorphic mutations underlie at least a subset of ASDs (Chahrour et al., 2012; Morrow et al., 2008), and together with a report on biallelic null mutations in this same issue of Neuron (Lim et al., 2013), provide strong evidence for a role of inherited recessive mutations in contributing to ASD. We demonstrate the utility of our approach in identifying three new ASD genes from a relatively small sample enriched for recessive inheritance. We present three families that simplify the identification of causative genes by narrowing genetic loci to 1%–3% of the genome and allow identification of single mutations that are rare and likely to be functional. These analyses demonstrate a strategy for dissection of an otherwise highly heterogeneous disorder. We present additional evidence that biallelic mutations occur in other smaller families, as well as in European American families from the Simons Simplex Collection. As high-quality whole-exome sequencing data from additional cohorts becomes available, it will be valuable to quantify the prevalence of these biallelic mutations in ASD in general. A common theme of many of the mutations identified in this cohort is hypomorphic mutations that partially impair gene function, though one or two null mutations are also identified.

The finding of partially disabling mutations in AMT and PEX7 suggests that mild forms of neurometabolic conditions may present with autistic symptoms, although such very mild mutations may be quite rare, especially in nonconsanguineous populations. Although several neurometabolic disorders have been associated with autistic symptoms (Zecavati and Spence, 2009; Novario et al., 2012), milder forms of other metabolic conditions may also be potentially missed by current newborn or biochemical screening tests, which have limits to their sensitivity (Watson et al., 2006). In analogous fashion, the rare biallelic variants we identified in other syndromic neurodevelopmental genes (VPS13B/COH1, SYNE1, MECP2, POMGNT1) also seem to represent mutations in genes in which complete knockout causes more severe syndromes, but which present with milder ASD phenotypes when partially inactivated. Exome sequencing will likely improve our ability to recognize these difficult-to-diagnose cases. Metabolic conditions are especially critical to identify since for some neurometabolic conditions, interventions may be available.

In this study, we focused on identifying rare, deleterious, penetrant variants that are causative of ASD in the families in question. Our data does not rule out contributions of common variation to ASD in other cases. While common variants are under less selective pressure than rare variants and are more likely to be benign, the functional impact of most common variants is poorly understood. Some might be expected to lie in autism gene pathways, impact biochemical function, and modify disease risk. For example, a common deletion in TMLHE, encoding the first enzyme in carnitine biosynthesis, has been recently implicated as a risk factor for autism (Celestino-Soper et al., 2012).

Genes implicated in this study include ones known to regulate or be regulated by synaptic activity (MECP2, SYNE1) but also genes not traditionally thought of as having synaptic roles (AMT, PEX7, VPS13B/COH1). This could reflect an important role for nonsynaptic genes and suggest the involvement of hitherto unexpected pathways in ASDs. Alternatively, given the strength of genetic evidence implicating genes of the synapse as causative in ASDs, AMT, PEX7, and VPS13B/COH1 may have involvement in synaptic pathways that have yet to be characterized. AMT for example, regulates turnover of glycine, a crucial inhibitory neurotransmitter (Baer, 2009; Keck and White, 2009). PEX7 regulates peroxisomal protein import, and peroxisomes are abundant in dendrites (Kou et al., 2011). Finally, VPS13B/COH1 has essential roles in vesicle trafficking through the Golgi apparatus (Seifert et al., 2011). Hence, while null

---

(B) Mapping to a locus on chromosome 6. Genome-wide linkage plot (top) and maximum obtainable LOD score in the family across the interval (bottom).

(A) A homozygous missense mutation in the AU-3500 family disrupts a conserved tryptophan (p.W75C) (C) in the first WD40 repeat of PEX7, the receptor responsible for import of PTS2-containing proteins into the peroxisome (D), and an established cause of rhizomelic chondrodysplasia punctata.

(E) PEX7 W75C or S25F, a previously characterized mutation from a family with mild RCDP and ASD, result in partial loss of function in a peroxisomal import assay. In fibroblasts from patients with RCDP, PTS2-tagged mCherry accumulates in the cytoplasm due to lack of PEX7 transport activity (top). Transfection of wild-type PEX7 cDNA causes PTS2-mCherry to redistribute to small puncta, indicative of restoration of peroxisomal import (bottom). Transfection of mutant PEX7 W75C or S25F does not restore complete import, with a minority of cells showing partial import (middle). Quantification of defects in peroxisomal import mediated by ASD-associated PEX7 alleles, scored by visual assay. Error bars represent standard error (right).

(F) Immunoblotting of whole cell lysates illustrates deficient maturation of PTS2-targeted proteins in a RCDP cell line transfected with ASD-associated PEX7 alleles. AGPS, PhyH, and thiolase are imported into the peroxisome and undergo cleavage into a smaller, mature peptide, p, preprotein; m, mature protein; Beta-tubulin, loading control. Quantification of processing defects by densitometry of transfected cell lysates (right).
Figure 3. Identification of Mutations in SYNE1 in a Family with ASD
(A) AU-1600, a family with four children affected with ASD. Shaded symbols indicate affected individuals. WES was performed on samples from individuals indicated with a star. Genotyping by Sanger sequencing in additional family members was performed where indicated (+, reference allele; –, alternate allele).

(B) Mapping rules out the majority of the genome and points out to only two candidate loci, one on chromosome 6 and the other on chromosome 7. Genome-wide linkage plot (top) and maximum obtainable LOD score in the family across the interval (bottom).

(C) SYNE1 is a complex locus implicated in neuropsychiatric disease. SYNE1 encompasses multiple alternative transcripts (Known Genes, UCSC Genome Browser), and mutations have been associated with a wide range of neurodevelopmental phenotypes. The location of the recessively inherited missense change (legend continued on next page)
Inherited Causes of Autism

mutations in these genes may have effects in many tissues, hypomorphic mutations may cause subter defects primarily limited to neurons.

Our data support the interpretation that biallelic mutations in the proper setting can cause a spectrum of clinical phenotypes, which at one extreme cause a Mendelian disorder, but at the other extreme represent risk alleles for ASDs. In our multiplex pedigrees, siblings who share homozygosity for the identical biallelic mutation still can show a variety of phenotypes, ranging from ASD to intellectual disability, and including epilepsy and/or other features. This variable expressivity has parallels in known associations of ASD with Mendelian genes like FMR1 or TSC2, which are near fully penetrant for syndromic features of Fragile X or Tuberous Sclerosis, respectively, but only partially penetrant for ASD (Hagerman et al., 2010; Wiznitzer, 2004). Variability of phenotype is also characteristic of recurrent ASD-associated CNVs, such as 16p11.2, which has been linked not only to ASD but also to schizophrenia, epilepsy, ADHD, and obesity (McCarthy et al., 2009; Shinawi et al., 2010; Walters et al., 2010; Weiss et al., 2008). The common theme of variability of phenotype despite underlying shared genetic susceptibility increasingly suggests that highly penetrant mutations associated strictly with ASD, and never with other conditions, may be extremely rare or nonexistent.

Our data extend the observation that hypomorphic alleles can commonly cause conditions that may be dramatically different from null mutations in the same gene (Walsh and Engle, 2010). Hypomorphic, biallelic mutations, combined with CNVs and heterozygous stop mutations (Neale et al., 2012; O’Roak et al., 2012; Sanders et al., 2012) which completely inactivate one of two alleles, suggest that a common theme for ASD mutations in general might be partial loss of gene function and/or dosage sensitivity. In other words, ASD, and potentially other neuropsychiatric conditions, may be united by incomplete loss of function of specific synaptic genes. Such incomplete loss might provide a general model for the complex genetic architecture, and genetic heterogeneity, of ASDs. In this respect, neuropsychiatric conditions may increasingly come to be understood as much by their allelic architecture as by the specific causative genes.

EXPERIMENTAL PROCEDURES

Human Studies

All human studies were reviewed and approved by the institutional review board of the Boston Children’s Hospital, Beth Israel Deaconess Medical Center, and local institutions.

Patient Recruitment

The families presented were collected by the Homozygosity Mapping Collaborative for Autism (HMCA) (Morrow et al., 2008), with referral centers in Turkey, the Kingdom of Saudi Arabia, Kuwait, United Arab Emirates, Oman, Jordan, and Pakistan. Inclusion criteria included a diagnosis of autism or ASD by a neurologist, child psychiatrist, or psychologist and families with multiple affected children and/or suspected consanguinity. See Supplemental Experimental Procedures for further phenotyping details. Additional clinical information on families described here is provided in Supplemental Text.

Genome-wide Linkage and Homozygosity Scans

Genome-wide SNP screens were performed at the Broad Institute and Dana Farber Cancer Institute. Families were genotyped using Affymetrix 500K (NspI/Sty) or Affymetrix 6.0 microarrays. Linkage disequilibrium-based
SNP pruning was performed with PLINK, followed by filtering of loci homozygous in all samples and those with Mendelian inheritance errors. Multipoint LOD scores were calculated using MERLIN, assuming a recessive mode of disease inheritance, full penetrance, and a disease allele frequency of 0.0001. Runs of homozygosity were calculated using custom Perl scripts, allowing for no more than two consecutive heterozygous SNPs in a run and three heterozygous calls in every ten consecutive SNPs. Intervals homozygous for the same haplotype and shared by all affected individuals were used to narrow the locus in each family. See Supplemental Experimental Procedures for details.

Whole-Exome Sequencing and Data Analysis
DNA samples were sequenced at the Broad Institute. Whole blood DNA was subject to exome capture (SureSelect v2, Agilent Technologies) and whole-exome sequence (Illumina HiSeq) was obtained on a total of 277 affected children and 409 parents, with a mean target coverage of 85.6% at ≥20× and a mean read depth of 158×. For this study, families harboring known autism-associated CNVs were excluded (Supplemental Experimental Procedures). Reads were aligned to NCBI human genome build v37 and variants were called and annotated using GATK. ANNOVAR (Wang et al., 2010) and custom pipelines. All reported variants were confirmed by Sanger sequencing. See Supplemental Experimental Procedures for additional details.

SSC Exome Reanalysis
Exome data from 612 families from the Simons Simplex Collection were obtained from dbGAP and NDAR. Raw sequence reads were aligned with BWA and variants were called with Samtools and annotated as previously described (Sanders et al., 2012).

Sanger Resequencing
See Supplemental Experimental Procedures for details.

Data Visualization
See Supplemental Experimental Procedures for details.

AMT Expression and Enzymatic Assays
Wild-type and mutant human AMT proteins with a C-terminal His6-tag were expressed and purified as previously described (Okamura-Ikeda et al., 2005). I308F, I308A, D198G, or D198A substitutions were introduced using site-directed mutagenesis, and enzymatic activities were determined as previously described (Okamura-Ikeda et al., 2010).

For heat stability studies, wild-type and mutant AMTs (about 0.5 mg/ml in 20 mM Tris-HCl [pH 7.5], 1 mM DTT, 20 mM (p-amidinophenyl) methanesulfonyl fluoride, and 10% glycerol) were incubated for 1, 2, and 3 hr at 37°C and 42°C. After incubation, the solutions were centrifuged and the protein concentrations in the supernatants were determined using Coomassie Plus (Thermo Scientific, USA) with BSA as standard. The remaining protein concentrations in the supernatant were showed as a percent of the initial concentrations.

PEX7 Peroxisomal Import Assays
A peroxisomal import marker was generated by fusing mCherry fluorescent protein to the PT52 signal located in the first 26 amino acids of rat 3-ke- toacyl-CoA thiolase [P07871.2] (Tsukamoto et al., 1994). N-terminal c-myc tagged variants of PEX7 (W75C and S25F) were engineered using PCR based site-directed mutagenesis of the N-myc-PEX7 cDNA [NM_000288] in pCDNA1. PEX7 and PTS2-mCherry were transiently transfected into an immortalized RCDP1 fibroblast line with a PEX7 null genotype (p.L292X); [S132X] and processed at 3 days for direct and indirect immunofluorescence as previously reported (Braverman et al., 2002). Recovery of peroxisomal import was assessed by blinded visual scoring of 100 cells each from 3 separate transfections. Peroxisomal import was confirmed by colocalization of the peroxisome membrane protein PEX14. Whole cell lysates from similarly transfected fibroblasts were used for immunoblotting with antibodies to the endogenous PTS2 proteins thiolase, PthYH, and AGPS (Zhang et al., 2010). PEX7 protein expression was confirmed with a c-myc antibody (SC789, Santa Cruz Biotechnology Inc., Santa Cruz, CA).

RNaseq of Human Neurons
Primary human neuronal cells were purchased from Sciencell (Carlsbad, CA). For RNaseq experiments, neuronal cultures from three biological replicates were grown for around two weeks (DIV13–16). At the final day in culture, neurons in the experimental group were stimulated for 6 hr with 55 mM KCl and were harvested along with the unstimulated control neurons using Trizol (Invitrogen). Strand-specific and paired-end cDNA libraries were generated using the PE RNaseq library kit (Illumina). RNaseq was performed using HiSeq 2000 at the Broad Institute. 76-bp RNaseq reads were aligned to the human GRCh37/hg19 assembly using BWA. See Supplemental Experimental Procedures for details. For quantification of SYNEN expression in response to depolarization, for each biological replicate, expression levels (normalized reads per bp) of individual exons were calculated, which allowed the calculation of the average expression level over any isoform of SYNEN comprising subsets of
these exons. Then fold-change ratios (6 hr/unstimulated) of these levels were calculated for each replicate and isoform, and finally each isoform’s mean and standard error over the replicates’ fold changes.

**ChiPseq of Human Neurons**
The mini-Chip assays were performed as previously described (Adli and Bernstein, 2011) on human neuronal cells that had been cultured for around two weeks. Briefly, cells were cross-linked, lysed, and the fragmented chromatin was then immunoprecipitated with H3K27Ac (Abcam Cat# ab4728) and H3K27me3 (Millipore Cat# 074490) antibodies. The ChiP DNA was recovered and precipitated following standard procedures. The ChiP DNA libraries were then constructed using ChiP-Seq DNA Sample Prep Kit (Illumina) and subsequently sequenced using HiSeq 2000 (Illumina) in Biopolymers facility at Harvard Medical School. ChiPseq reads were aligned to the human genome (GRCh37/hg19 assembly). See Supplemental Experimental Procedures for details.

**Data Access**
Whole-exome sequence data is available online (The National Database for Autism Research [NDAR] Collection ID: NDARCOL0001918).

**SUPPLEMENTAL INFORMATION**
Supplemental Information includes five figures, five tables, Supplemental Experimental Procedures, and Supplemental Text and can be found with this article online at http://dx.doi.org/10.1016/j.neuron.2012.11.002.

**ACKNOWLEDGMENTS**
We are grateful to Ed Gilmore, Chiara Manzini, Jenny Yang, and Mark Daly for stimulating discussions and helpful comments on the manuscript and Thomas Lehner for support from the National Institute of Mental Health (NIMH). We are also grateful for the participation of the many families that enrolled in our studies as well as for the collaborative support of the Kuwait Center for Autism and the Dubai Autism Center. T.W.Y. was supported by a National Institute of Health (NIH) T32 grant (T32 NS007484-08), the Clinical Investigator Training Program (CITP) at Harvard-MIT Health Sciences and Technology and Beth Israel Deaconess Medical Center in collaboration with Pfizer, Inc. and Merck & Company, Inc., and the Nancy Lurie Marks Junior Faculty MerIT Fellowship. M.H.C. was supported by a NIH T32 grant (T32 NS007473-12), G.H.M. was supported by the Young Investigator Award of NARSAD as a NARSAD Lieber Investigator. A.P. was supported by the National Institutes of Neurological Disease and Stroke (K23NS069784), A.M.D. was supported by the National Institute of General Medical Sciences (T32GM07753). Research was supported by grants from the National Institute of Mental Health (RO1 MH083565; 1RC2MH089952) to C.A.W., the NIH to M.E.G. (RO1 NS048276), the NIMH to E.M.M. (1K23MH080954-01), the Dubai Harvard Foundation for Medical Research, the Nancy Lurie Marks Foundation, the Simons Foundation, the Autism Consortium, and the Manton Center for Orphan Disease Research. Sequencing at the Broad Institute was supported by the ARRA Grand Opportunities grant 1RC2MH089952. C.A.W. is an Investigator of the Howard Hughes Medical Institute. T.W.Y. identified the Howard Hughes Medical Institute. T.W.Y. identified AMT, PEX7, and SYNE1 mutations, helped design AMT and PEX7 functional studies, designed and performed exome sequencing analyses for candidate genes, contributed to CNV analyses, and wrote the manuscript. M.H.C. designed and performed exome sequencing analyses for candidate genes, analyzed Sanger validation data and SSC exome data, and wrote the manuscript. M.E.C. helped analyze AU-1700 and AU-3500. S.J. designed PEX7 functional experiments with N.E.B. and performed PEX7 functional experiments with N.E.B. and S.J. performed them. K.O.-I. designed and performed AMT functional studies and analyzed results. B.A. designed and analyzed RNAseq, ChiPseq, and qPCR experiments. D.A.H. analyzed RNAseq and qPCR experiments. M.A. performed ChiPseq experiments, and A.N.M. analyzed the data. A.M.D. performed RACE experiments for SYNE1. K.S.-A. and K.M. designed the CNV analysis, and K.S.-A. compiled the CNV catalog and identified pathogenic CNVs. E.T.L. and S.J.S. helped analyze SSC whole-exome data. G.H.M. performed clinical phenotyping of Middle Eastern families as well as detailed molecular analyses of AU-8600. J.N.P. organized clinical information and patient samples. C.M.S. assisted with exome sequencing analyses and performed follow-up Sanger validation. J.M.F. and J.R. performed follow-up Sanger validation. R.H.N. performed clinical phenotyping of AU-17800 and AU-17800. R.M.J. performed clinical phenotyping of AU-1600 and AU-10000, and AU-10200. R.S.H. performed genome-wide linkage studies and homozygosity analyses. B.Y.K. assisted with characterization of the AMT mutation. M.A.-S. organized clinical information and patient samples and referred AU-17700 and AU-17800. N.M.M. referred and clinically characterized AU-6200, AU-4400, AU-4900, AU-5700, AU-6100, AU-6200, AU-6300, AU-8600, AU-11100, AU-11800, AU-11900, AU-12100, AU-12400, AU-14900, AU-15800, AU-16700, AU-20700, AU-22500, AU-23400, and AU-24300. A.H. referred and characterized AU-3500 and AU-3600. S.B. referred and characterized AU-1700. G.G. referred and characterized AU-1700 and AU-17800. E.L. and A.P. performed clinical phenotyping of AU-1600, AU-10000, and AU-10200. O.O. referred and characterized AU-13100, AU-13400, AU-18000, AU-20300, and AU-22000. S.A.-S., S.A.-A., and L.B. referred and characterized AU-1600. S.A.-S. referred and characterized AU-8600. T.B.-O. and A.S.T. referred and characterized AU-21100. L.A.-G. and V.E. referred and characterized AU-3200. C.R.S. organized and coordinated exome sequencing. L.R. evaluated the second compound heterozygous PEX7 family. S.B.G. directed exome sequencing. K.M. designed the CNV analysis. M.W.S. oversaw SSC exome analyses. M.E.G. oversaw SYNE1 RNAseq and qPCR experiments. H.T. designed and performed AMT functional experiments. N.E.B. designed PEX7 functional experiments, recruited the nonconsanguineous family with two sisters affected by PEX7 mutation, and contributed to interpretation of PEX7 sequencing data. E.M.M. helped characterize AU-1700, performed linkage studies on AU-1600, AU-1700, and AU-3500, helped design the exome sequencing experiment, and contributed to finding the SYNE1 mutation. C.A.W. directed the overall research and wrote the manuscript.

Accepted: November 2, 2012
Published: January 23, 2013

**REFERENCES**


Inherited Causes of Autism


Inherited Causes of Autism


